Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol for Detection of Cellular Inflammation in the Heart
NCT02319278Phase 3Completed
- Sponsor
- University of Edinburgh
- Start
- Dec 2014
- Primary completion
- Nov 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ferumoxytol in cardiac transplant rejection (HTR), myocarditis and cardiac sarcoidosis (CS) (4 arms), sponsored by University of Edinburgh. Primary endpoint: Assessment of Myocardial Cellular Inflammation at 1 year. Started Dec 2014; status: completed.
02
Drugs
ferumoxytol
03
Conditions
cardiac transplant rejection (HTR)myocarditiscardiac sarcoidosis (CS)
Beyond the preview
Go deeper on NCT02319278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319278.